New drug combo for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of three drugs—anlotinib, benmelstobart, and chemotherapy—as a first treatment for pancreatic cancer that has spread. The goal is to see if this combo can shrink tumors or slow the cancer's growth better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pancreatic cancer that has spread to other parts of the body (metastatic).
- You have not had any previous treatment for metastatic pancreatic cancer, though you may qualify if your cancer returned more than 6 months after prior treatment for earlier-stage disease.
- You have at least one tumor that can be measured on a scan.
- You are generally able to care for yourself (ECOG score 0-1) and have a life expectancy of at least 3 months.
- Your blood counts, liver, kidney, and clotting function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy with two newer drugs (SHR-1701 and apatinib) as the first treatment for advanced pancreatic cancer. The goal is to see if this combination is safe and effective in slowing cancer growth.
This trial tests a combination of two chemotherapy drugs, nab-paclitaxel and gemcitabine, as the first treatment for pancreatic cancer that has spread. The goal is to shrink tumors and improve survival.
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This trial tests a combination of four drugs (surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine) as a first treatment for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if this combination helps shrink tumors and improve survival.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.